Bleomycin Induces Molecular Changes Directly Relevant to Idiopathic Pulmonary Fibrosis: A Model for "Active" Disease

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Peng, Ruoqi ^a   Sridhar, Sriram ^a   Tyagi, Gaurav ^a   Phillips, Jonathan E ^a   Garrido, Rosario ^a   Harris, Paul ^a   Burns, Lisa ^a   Renteria, Lorena ^a   Woods, John ^a   Chen, Leena ^a   Allard, John ^a   Ravindran, Palanikumar ^a   Bitter, Hans ^a   Liang, Zhenmin ^a   Hogaboam, Cory M ^b   Kitson, Chris ^a   Budd, David C ^a   Fine, Jay S ^a,d   Bauer, Carla M T ^a   Stevenson, Christopher S ^a,c  

^a HOFFMANN LA ROCHE INC   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^d BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ISOLATION; CLINICAL ARTICLE; CONTROLLED STUDY; FIBROSING ALVEOLITIS; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; LUNG FIBROBLAST; LUNG FIBROSIS; MALE; MOLECULAR PATHOLOGY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; SIGNAL TRANSDUCTION;

AIRWAY REMODELING; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; BLEOMYCIN; CLUSTER ANALYSIS; DISEASE MODELS, ANIMAL; FIBROBLASTS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; IMIDAZOLES; INFLAMMATION; LUNG; MALE; MICE; MITOSIS; PROTEIN-SERINE-THREONINE KINASES; QUINOXALINES; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; SIGNAL TRANSDUCTION;

MUS;

EID: 84875649092     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0059348     Document Type: Article

References (31)

1. King TE Jr, Pardo A, Selman M, (2011) Idiopathic pulmonary fibrosis. Lancet 378: 1949-1961.
2. Ley B, Collard HR, King TE Jr, (2011) Clinical course and prediction of survival in idiopathic pulmonary fibrosis. American journal of respiratory and critical care medicine 183: 431-440.
3. Moeller A, Ask K, Warburton D, Gauldie J, Kolb M, (2008) The bleomycin animal model: a useful tool to investigate treatment options for idiopathic pulmonary fibrosis? The international journal of biochemistry & cell biology 40: 362-382.
4. Higashiyama H, Yoshimoto D, Kaise T, Matsubara S, Fujiwara M, et al. (2007) Inhibition of activin receptor-like kinase 5 attenuates bleomycin-induced pulmonary fibrosis. Experimental and molecular pathology 83: 39-46.
5. Gross TJ, Hunninghake GW, (2001) Idiopathic pulmonary fibrosis. The New England journal of medicine 345: 517-525.
6. Degryse AL, Tanjore H, Xu XC, Polosukhin VV, Jones BR, et al. (2010) Repetitive intratracheal bleomycin models several features of idiopathic pulmonary fibrosis. American journal of physiology Lung cellular and molecular physiology 299: L442-452.
7. Bild AH, Yao G, Chang JT, Wang Q, Potti A, et al. (2006) Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 439: 353-357.
8. Konishi K, Gibson KF, Lindell KO, Richards TJ, Zhang Y, et al. (2009) Gene expression profiles of acute exacerbations of idiopathic pulmonary fibrosis. American journal of respiratory and critical care medicine 180: 167-175.
9. Scotton CJ, Chambers RC, (2007) Molecular targets in pulmonary fibrosis: the myofibroblast in focus. Chest 132: 1311-1321.
10. Thomas M, Docx C, Holmes AM, Beach S, Duggan N, et al. (2009) Activin-like kinase 5 (ALK5) mediates abnormal proliferation of vascular smooth muscle cells from patients with familial pulmonary arterial hypertension and is involved in the progression of experimental pulmonary arterial hypertension induced by monocrotaline. The American journal of pathology 174: 380-389.
11. Grygielko ET, Martin WM, Tweed C, Thornton P, Harling J, et al. (2005) Inhibition of gene markers of fibrosis with a novel inhibitor of transforming growth factor-beta type I receptor kinase in puromycin-induced nephritis. Journal of Pharmacology Experimental Therapeutics 313: 943-951.
12. Kinder BW, Brown KK, Schwarz MI, Ix JH, Kervitsky A, et al. (2008) Baseline BAL neutrophilia predicts early mortality in idiopathic pulmonary fibrosis. Chest 133: 226-232.
13. Chung MP, Monick MM, Hamzeh NY, Butler NS, Powers LS, et al. (2003) Role of repeated lung injury and genetic background in bleomycin-induced fibrosis. American journal of respiratory cell and molecular biology 29: 375-380.
14. Harris P, Sridhar S, Peng R, Phillips JE, Cohn RG, et al. (2012) Double-stranded RNA induces molecular and inflammatory signatures that are directly relevant to COPD.Mucosal immunology 2012 Sep 19 e-pub.
15. du Bois RM, Nathan SD, Richeldi L, Schwarz MI, Noble PW (2012) Idiopathic Pulmonary Fibrosis: Lung Function is a Clinically Meaningful Endpoint for Phase 3 Trials. American journal of respiratory and critical care medicine.
16. Qunn L, Takemura T, Ikushima S, Ando T, Yanagawa T, et al. (2002) Hyperplastic epithelial foci in honeycomb lesions in idiopathic pulmonary fibrosis. Virchows Archiv: an international journal of pathology 441: 271-278.
17. Venkatesan N, Pini L, Ludwig MS, (2004) Changes in Smad expression and subcellular localization in bleomycin-induced pulmonary fibrosis. American journal of physiology Lung cellular and molecular physiology 287: L1342-1347.
18. Coker RK, Laurent GJ, Shahzeidi S, Lympany PA, du Bois RM, et al. (1997) Transforming growth factors-beta 1,-beta 2, and-beta 3 stimulate fibroblast procollagen production in vitro but are differentially expressed during bleomycin-induced lung fibrosis. The American journal of pathology 150: 981-991.
19. Swiderski RE, Dencoff JE, Floerchinger CS, Shapiro SD, Hunninghake GW, (1998) Differential expression of extracellular matrix remodeling genes in a murine model of bleomycin-induced pulmonary fibrosis. The American journal of pathology 152: 821-828.
20. Wynn TA, Ramalingam TR, (2012) Mechanisms of fibrosis: therapeutic translation for fibrotic disease. Nature medicine 18: 1028-1040.
21. Trujillo G, Meneghin A, Flaherty KR, Sholl LM, Myers JL, et al. (2010) TLR9 differentiates rapidly from slowly progressing forms of idiopathic pulmonary fibrosis. Science translational medicine 2: 57ra82.
22. Nakao A, Fujii M, Matsumura R, Kumano K, Saito Y, et al. (1999) Transient gene transfer and expression of Smad7 prevents bleomycin-induced lung fibrosis in mice. The Journal of clinical investigation 104: 5-11.
23. Zhao J, Shi W, Wang YL, Chen H, Bringas P Jr, et al. (2002) Smad3 deficiency attenuates bleomycin-induced pulmonary fibrosis in mice. American journal of physiology Lung cellular and molecular physiology 282: L585-593.
24. Oga T, Matsuoka T, Yao C, Nonomura K, Kitaoka S, et al. (2009) Prostaglandin F(2alpha) receptor signaling facilitates bleomycin-induced pulmonary fibrosis independently of transforming growth factor-beta. Nature medicine 15: 1426-1430.
25. Phillips JE, Peng R, Burns L, Harris P, Garrido R, et al. (2012) Bleomycin induced lung fibrosis increases work of breathing in the mouse. Pulmonary pharmacology & therapeutics 25: 281-285.
26. Koch LG, Britton SL, (2001) Artificial selection for intrinsic aerobic endurance running capacity in rats. Physiological genomics 5: 45-52.
27. Ashcroft T, Simpson JM, Timbrell V, (1988) Simple method of estimating severity of pulmonary fibrosis on a numerical scale. Joural of clinical pathology 41: 467-470.
28. Benjamini Y, Hochberg Y, (1995) Controlling the False Discovery Rate- a Practical and Powerful Approach to Multiple Testing. Journal of the Royal Statistical Society Series B-Methodological 57: 289-300.
29. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, et al. (2005) Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proceedings of the national academy of sciences U S A 102: 15545-15550.
30. Hogaboam CM, Carpenter KJ, Evanoff H, Kunkel SL, (2005) Approaches to evaluation of fibrogenic pathways in surgical lung biopsy specimens. Methods in molecular medicine 117: 209-221.
31. Pechkovsky DV, Prele CM, Wong J, Hogaboam CM, McAnulty RJ, et al. (2012) STAT3-mediated signaling dysregulates lung fibroblast-myofibroblast activation and differentiation in UIP/IPF. American journal of pathology 180: 1398-1412.